Construction and validation of a novel SUMOylation-related IncRNAs signature for predicting the prognosis,tumor immune microenvironment,and therapeutic sensitivity of lung adenocarcinoma  

作　　者：Jie Cai Weizhong Ruan Zida Wang Gongzhe Liu Bei Yang Hao Wang Deping Zhao Chang Chen Xiaogang Zhao 

机构地区：[1]Department of Thoracic Surgery,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [2]Department of Thoracic Surgery,Clinical Oncology School of Fujian Medical University,Fujian Cancer Hospital(Fujian Branch of Fudan University Shanghai Cancer Center),Fuzhou,Fujian 350014,China [3]Department of Emergency,Shanghai Pulmonary Hospital,School of Medicine,Tongji University,Shanghai 200433,China [4]Department of Cardiothoracic Surgery,People's Hospital Affiliated to Shandong First Medical University,Jinan,Shandong 271199,China

出　　处：《Genes & Diseases》2025年第2期102-105,共4页基因与疾病(英文)

基　　金：supported by the Shanghai Sailing Program (China) (No.22YF1437600 to J.C.);the Programs of Shanghai Pulmonary Hospital (China) (No.fkzr2477 to J.C.).

摘　　要：Lung adenocarcinoma(LUAD)is the most prevalent subtype of lung cancer and the leading cause of cancer deaths worldwide.1 Despite immunotherapy,radiotherapy,and chemotherapy advances,treatment outcomes remain unsatisfactory.2Thus,prognostic models that accurately predict patient prognosis and guide individualized treatment are desperately needed.

关 键 词：ADENOCARCINOMA PROGNOSIS lung 

分 类 号：R73[医药卫生—肿瘤]